Biohope is an early commercial stage R&D company dedicated to the development of precision medicine IVD tools and unique patient knowledge for chronic inflammatory conditions. Founded in 2015, it has received 3.8M EUR funding through the European Commission’s H2020 program, and 2.8M EUR through private funding. It employs 19 professionals in R&D, IT, Medical Affairs, Financial, Legal, Regulatory, Quality Control and BD&L.
Biohope lead product, Immunobiogram®, is a novel and unique, patented in vitro diagnostic device which generates a report for the physicians to optimize each individual immunosuppressive therapy. It is a combination of a bioassay and database analysis tools .
The Immunobiogram® in Kidney Transplantation is the first product from our technological platform. We have successfully finished a National and an International clinical study (performed in Spain, USA, Germany, Denmark, Poland) that have demonstrated the effectiveness of Immunobiogram®
We have a patent published for EU, a PCT ongoing, an ISO 13485 certification, and a CE mark expected by Q3 2020.
In our pipeline, based on Immunobiogram® technology, adaptation is ongoing for Rheumatoid Arthritis, and planned for Lupus Nephritis. Further adaptations of the Immunobiogram® to other conditions that require a patient to be on immunosupressants (transplants of other organs, additional autoimmune diseases) will be assessed in the future.